Edgewise Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Edgewise Therapeutics sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).

15 total trials 2 currently recruiting 8 completed early-phase tilt top decile by trial count

Edgewise Therapeutics: 15 sponsored US clinical trials, 2 recruiting.

Edgewise Therapeutics sponsors 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Duchenne Muscular Dystrophy, with 2 trials.

Top-decile sponsor footprint

Edgewise Therapeutics ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

15 total, page 1 of 1

RECRUITING Phase 1

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

NCT07324616
RECRUITING Phase 1

A Study of EDG-15400 in Healthy Adults

NCT07177066
ACTIVE NOT RECRUITING Phase 2

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

NCT06347159
ACTIVE NOT RECRUITING Phase 2

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy

NCT06100887
ACTIVE NOT RECRUITING Phase 2

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

NCT05291091
ACTIVE NOT RECRUITING Phase 2

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

NCT05540860
NOT YET RECRUITING Phase 1

A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults

NCT07456059
COMPLETED Phase 1

A Study to Evaluate EDG-7500 in People With Renal Impairment

NCT07034768
COMPLETED Phase 1

A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers

NCT06916897
COMPLETED Phase 1

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

NCT06738836
COMPLETED Phase 1

A Study of EDG-7500 in Healthy Adults

NCT06011317
COMPLETED Phase 1

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

NCT05730842
COMPLETED Phase 1

A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling

NCT05492734
COMPLETED Phase 1

A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy

NCT05160415
COMPLETED Phase 1

A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults

NCT04585464

Phase Distribution

PhaseTrial count
Phase 1 11
Phase 2 4

Therapeutic Areas

Duchenne Muscular Dystrophy 2
Hepatic Impairment (HI) 1
Becker Muscular Dystrophy 1
Hypertrophic Cardiomyopathy 1
Healthy Adults 1

What is open in the Edgewise Therapeutics pipeline

2 recruiting of 15 indexed (13% open); 8 completed (53%).

Phase mix: 0 late (III/IV) vs 15 early (I/II) (early-phase heavy).

Top condition: Duchenne Muscular Dystrophy (2 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Edgewise Therapeutics: open-pipeline peers nationwide

Peers matched on 15 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Edgewise Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 101520253035 0%10%20%30%40% Total trials Recruiting share Edgewise TherapeuticsAllakosArbor Research Collaborative for HealthArena PharmaceuticalsArrowhead PharmaceuticalsChiesi Farmaceutici S.p.A.Dizal PharmaceuticalsEpicentRxEuropean Organisation for Research and Treatment of Cancer - EORTC
Edgewise Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Edgewise Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 15 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Edgewise Therapeutics page

15 registered trials is a research-attention snapshot, not an endorsement of Edgewise Therapeutics or any single study.

  • 2 of Edgewise Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Duchenne Muscular Dystrophy is the condition Edgewise Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Duchenne Muscular Dystrophy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Edgewise Therapeutics pipeline card: 15 registered trials from official public datasets.Report a data error.